Диссертация (Разработка технологии и состава иммунолипосомальной формы митоксантрона с гуманизированными моноклональными антителами к HER-2 антигену), страница 23
Описание файла
Файл "Диссертация" внутри архива находится в папке "Разработка технологии и состава иммунолипосомальной формы митоксантрона с гуманизированными моноклональными антителами к HER-2 антигену". PDF-файл из архива "Разработка технологии и состава иммунолипосомальной формы митоксантрона с гуманизированными моноклональными антителами к HER-2 антигену", который расположен в категории "". Всё это находится в предмете "фармацевтика" из Аспирантура и докторантура, которые можно найти в файловом архиве МГМУ им. Сеченова. Не смотря на прямую связь этого архива с МГМУ им. Сеченова, его также можно найти и в других разделах. , а ещё этот архив представляет собой кандидатскую диссертацию, поэтому ещё представлен в разделе всех диссертаций на соискание учёной степени кандидата фармацевтических наук.
Просмотр PDF-файла онлайн
Текст 23 страницы из PDF
G., Ringden O. Liposomal amphotericin B (AmBisome): safetydata from a phase II/III clinical trial //Journal of Antimicrobial Chemotherapy. – 1991. – Т.28. – №. suppl B. – С. 83-91.179. Millefiorini E. et al. Randomized placebo-controlled trial of mitoxantrone in relapsingremitting multiple sclerosis: 24-month clinical and MRI outcome //Journal of neurology. –1997. – Т. 244. – №. 3. – С. 153-159.180. Milsmann M. H. W., Schwendener R. A., Weder H. G.
The preparation of large singlebilayer liposomes by a fast and controlled dialysis //Biochimica et Biophysica Acta (BBA)Biomembranes. – 1978. – Т. 512. – №. 1. – С. 147-155.181. Mitra A., Lee C. H., Cheng K. Advanced drug delivery. – John Wiley & Sons, 2013.182. Moser C., Metcalfe I. C., Viret J. F. Virosomal adjuvanted antigen delivery systems//Expert review of vaccines.
– 2003. – Т. 2. – №. 2. – С. 189-196.183. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application toproliferation and cytotoxicity assays //Journal of immunological methods. – 1983. – Т. 65.– №. 1-2. – С. 55-63.184. Mozafari M. R. Liposomes: an overview of manufacturing techniques //Cellular andMolecular Biology Letters. – 2005.
– Т. 10. – №. 4. – С. 711.185. Mozafari M. R. Liposomes: an overview of manufacturing techniques //Cellular andMolecular Biology Letters. – 2005. – Т. 10. – №. 4. – С. 711.186. Murdock K. C. et al. Antitumor agents. 1. 1, 4-Bis [(aminoalkyl) amino]-9, 10anthracenediones //Journal of medicinal chemistry. – 1979. – Т. 22. – №. 9. – С. 10241030.187. Murdock K. C. Novel 1, 4-bis (substituted-amino)-5, 8-dihydroxyanthraquinones andleuco bases thereof : пат. 4410524 США.
– 1983.188. Myers C. E. et al. Anthracycline and anthracenedione-based anticancer agents //byLown JW, Elsevier, Amsterdam. – 1988. – С. 527-569.189. Nayar R., Hope M. J., Cullis P. R. Generation of large unilamellar vesicles from longchain saturated phosphatidylcholines by extrusion technique //Biochimica et BiophysicaActa (BBA)-Biomembranes. – 1989. – Т. 986.
– №. 2. – С. 200-206.190. Nichols J. W., Deamer D. W. Catecholamine uptake and concentration by liposomesmaintaining pH gradients //Biochimica et Biophysica Acta (BBA)-Biomembranes. – 1976.– Т. 455. – №. 1. – С. 269-271.191. Novopharm Limited. Mitoxantrone Injection Product Monograph. Toronto, Ontario; 19May 2005.192.
Ohkuma S., Poole B. Fluorescence probe measurement of the intralysosomal pH inliving cells and the perturbation of pH by various agents //Proceedings of the NationalAcademy of Sciences. – 1978. – Т. 75. – №. 7. – С. 3327-3331.193. Ohsawa T, Miura H, Harada K. Improvement of encapsulation efficiency of watersoluble drugs in liposomes formed by the freeze-thawing method //Chemical andpharmaceutical bulletin.
– 1985. – Т. 33. – №. 9. – С. 3945-3952.131194. Okusanya Ó. O. et al. Pharmacokinetic and pharmacodynamic evaluation of liposomalamikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection//Antimicrobial agents and chemotherapy. – 2009. – Т. 53. – №. 9. – С. 3847-3854.195. O'Neil M.
J. The Merck index: an encyclopedia of chemicals, drugs, and biologicals. –RSC Publishing, 2013.196. Papahadjopoulos D. P., Szoka Jr F. C. By forming an emulsion, evaporation of theorganic solvent to form a gel : пат. 4235871 США. – 1980.197. Park J. W. et al. Development of anti-p185HER2 immunoliposomes for cancer therapy//Proceedings of the National Academy of Sciences.
– 1995. – Т. 92. – №. 5. – С. 13271331.198. Park Y. S. Tumor-directed targeting of liposomes //Bioscience reports. – 2002. – Т. 22.– №. 2. – С. 267-281.199. Participants V. R. Guidelines for using verteporfin (Visudyne) in photodynamic therapyfor choroidal neovascularization due to age-related macular degeneration and other causes:update //Retina.
– 2005. – Т. 25. – №. 2. – С. 119-134.200. Patel H. M. Serum opsonins and liposomes: Their interaction and opsonophagocytosis//Critical reviews in therapeutic drug carrier systems. – 1991. – Т. 9. – №. 1. – С. 39-90.201. Patel H. M., Tuzel N. S., Ryman B. E. Inhibitory effect of cholesterol on the uptake ofliposomes by liver and spleen //Biochimica et Biophysica Acta (BBA)-General Subjects. –1983.
– Т. 761. – №. 2. – С. 142-151.202. Perez-Soler R. Liposomes as carriers of antitumor agents: toward a clinical reality//Cancer treatment reviews. – 1989. – Т. 16. – №. 2. – С. 67-82.203. Perry P. J. et al. 1, 4-and 2, 6-disubstituted amidoanthracene-9, 10-dione derivatives asinhibitors of human telomerase //Journal of medicinal chemistry. – 1998. – Т. 41. – №. 17.– С. 3253-3260.204. Phuphanich S. et al. A pharmacokinetic study of intra-CSF administered encapsulatedcytarabine (DepoCyt®) for the treatment of neoplastic meningitis in patients with leukemia,lymphoma, or solid tumors as part of a phase III study //Journal of neuro-oncology.
– 2007.– Т. 81. – №. 2. – С. 201-208.205. Pick U. Liposomes with a large trapping capacity prepared by freezing and thawing ofsonicated phospholipid mixtures //Archives of Biochemistry and Biophysics. – 1981. – Т.212. – №. 1. – С. 186-194.206. Poste G., Kirsh R., Koestler T. The challenge of liposome targeting in vivo //Liposometechnology. – 1984. – Т. 3.
– С. 1-28.207. Pratt W. B. et al. The Anticancer Drugs, 1994 //Oxford University, Oxford,(b),Takeuchi Y., Kitaomo M., Chang MR, Shirasaka S., Shimamura C., Okuno Y., Yamato M.,Harayama T., Chem. Pharm. Bull. – 1997. – Т. 45. – С. 2096.208. Riaz M. Liposomes preparation methods //Pak J Pharm Sci. – 1996. – Т. 9.
– №. 1. – С.65-77.209. Robinson J., Lee V. H. L. (ed.). Controlled drug delivery: fundamentals andapplications. – Informa Health Care, 1987. – Т. 29. – С. 433-465.210. Rodriguez M. A. et al. Vincristine sulfate liposomes injection (Marqibo) in heavilypretreated patients with refractory aggressive non‐Hodgkin lymphoma //Cancer.
– 2009. –Т. 115. – №. 15. – С. 3475-3482.211. Rosenthal D. I. et al. A Phase I study of SPI-077 (Stealth® liposomal cisplatin)concurrent with radiation therapy for locally advanced head and neck cancer//Investigational new drugs. – 2002. – Т. 20. – №. 3. – С. 343-349.212. Sahil K. et al. Stealth liposomes: a review //Int J Res Ayurveda Pharm. – 2011. – Т. 2. –№. 5.213. Sapra P. et al.
Improved therapeutic responses in a xenograft model of human Blymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via132anti-CD19 IgG2a or Fab′ fragments //Clinical cancer research. – 2004. – Т.
10. – №. 3. – С.1100-1111.214. Sapra P., Allen T. M. Internalizing antibodies are necessary for improved therapeuticefficacy of antibody-targeted liposomal drugs //Cancer Research. – 2002. – Т. 62. – №. 24.– С. 7190-7194.215. Sarris A. H. et al. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: earlyresults of an ongoing phase II trial //Annals of Oncology. – 2000. – Т. 11. – №. 1. – С. 6972.216. Schieren H. et al. Comparison of large unilamellar vesicles prepared by a petroleumether vaporization method with multilamellar vesicles: ESR, diffusion and entrapmentanalyses //Biochimica et Biophysica Acta (BBA)-General Subjects.
– 1978. – Т. 542. – №.1. – С. 137-153.217. Schuler U. et al. Pharmacokinetics and Metabolism of Mitoxantrone A Review//Clinical pharmacokinetics. – 1990. – Т. 18. – №. 5. – С. 365-380.218. Sekretariat R. L. Rote Liste 1998. – 1998.219. Semple S. C. et al. Optimization and characterization of a sphingomyelin/cholesterolliposome formulation of vinorelbine with promising antitumor activity //Journal ofpharmaceutical sciences. – 2005. – Т. 94. – №. 5. – С. 1024-1038.220.
Seymour L. W. Passive tumor targeting of soluble macromolecules and drug conjugates//Critical reviews in therapeutic drug carrier systems. – 1991. – Т. 9. – №. 2. – С. 135-187.221. Shmeeda H. et al. Her2-targeted pegylated liposomal doxorubicin: retention of targetspecific binding and cytotoxicity after in vivo passage //Journal of Controlled Release. –2009. – Т. 136. – №. 2. – С.
155-160.222. Shmeeda H. et al. Her2-targeted pegylated liposomal doxorubicin: retention of targetspecific binding and cytotoxicity after in vivo passage //Journal of Controlled Release. –2009. – Т. 136. – №. 2. – С. 155-160.223. Silvestri S., Gabrielson G., Wu L. L. Effect of terminal block on the microfluidizationinduced degradation of a model ABA block copolymer //International journal ofpharmaceutics. – 1991. – Т. 71.
– №. 1. – С. 65-71.224. Silvestri S., Ganguly N., Tabibi E. Predicting the effect of nonionic surfactants ondispersed droplet radii in submicron oil-in-water emulsions //Pharmaceutical research. –1992. – Т. 9. – №. 10. – С. 1347-1350.225. Singer S. J., Nicolson G. L.
